British pharmaceutical giant GSK completed a landmark acquisition of Nuvalent, Inc., a clinical-stage oncology biopharmaceutical company, in a transaction valued at approximately $10.6 billion. This major corporate buyout successfully added three advanced lung cancer assets—including next-generation precision kinase inhibitors like zidesamtinib and neladalkib—to GSK's expanding global specialty oncology portfolio, reinforcing its competitive standing in targeted cancer therapies.